Calcinosis cutis in the course of Crest´Syndrome
Keywords:
calcinosis cutis, Crest´syndrome, systemic sclerosis, sclerodermaAbstract
Systemic sclerosis is an chronic multiorganic entity of unknown cause, with immunologic association. This pathology is classified in diffuse cutaneous systemic sclerosis and limited cutaneous systemic sclerosis, in the second the skin thickness is in fingers, called “sclerodactilia”, distal part of extremities and the face, has been associate to Crest syndrome. Is defined as presence of calcinosis, Raynaud phenomenon, gastroesophageal reflux, sclerodactilia and telangiectasia. 35 years female with Crest syndrome diagnosis, where the principal manifestation is calcinosis cutis associated inflammatory lessons in anterior iliac spine, confused with bacterial abscess. She received surgical treatment with satisfactory evolution. We can conclude this treatment gave us, internal medicine and surgical department knowledgment to Crest syndrome treatment where the principal expression is calcinosis, easily confuse with septic processes where knowledge of personal record and semiology characteristics of calcic secretion hasn’t. One more time we can know the importance of a multidisciplinary work in the rheumatic diseases treatment.Downloads
References
Varga J, Abraham DJ. Systemic sclerosis: Paradigm multisystem fibrosing disorder. J Clin Invest. 2007;117:557-67.
Wollheim FA. Classification of systemic sclerosis: visions and reality. Rheumatology (Oxford). 2005;44:1212-6.
Doran MF, Pond GR, Crowson CS, O'Fallon WM, Gabriel SE. Trends in incidence and mortality in rheumatoid arthritis in Rochester, Minnesota, over a forty-year period. Arthritis Rheum. 2002;46(3):625-31.
Symmons D, Turner G, Webb R, Asten P, Barrett E, Lunt M, Silman A. The prevalence of rheumatoid arthritis in the United Kingdom: new estimates for a new century. Rheumatology. 2002;41(7):793-800.
Gabrielli A, Avvedimento EV, Krieg T. Review of epidemiology, pathogenesis, clinical manifestation, diagnosis, histolopathology, differential diagnosis, and treatment. Scleroderma. N Engl J Med. 2009;360:1989-2003.
Rosenbloom J, Castro SV, Jimenez SA. Narrative review. Fibrotic diseases: cellular and molecular mechanisms and novel therapies. Ann Intern Med. 2010;152:159-66.
Takehara K. Hypothesis: pathogenesis of systemic sclerosis. Journal of Rheumatology. 2003;30:755-59.
Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee, Preliminary criteria for the classification of systemic sclerosis (scleroderma). Diagnostic and Therapeutic Criteria Committee. Arthritis and Rheumatism. 1980;23:581-90.
Medsger TA. Systemic sclerosis (scleroderma): clinical aspects. In: Koopman WJ, editor. Arthritis and allied conditions: a textbook of rheumatology. 14th edition. Philadelphia: Ed. Lippincott Williams & Wilkins; 2000. p. 1590-624.
Valentini G, Bencivelli W, Bombardieri S, D’Angelo S, Della Rossa A, Silman AJ, Vlachoyiannopoulos PG. European Scleroderma Study Group to define disease activity criteria for systemic sclerosis. III. Assessment of the construct validity of the preliminary activity criteria. Annals of the Rheumatic Diseases. 2003;62(9):901-03.
Avouac J, Fransen J, Walker UA, Riccieri V, Smith V, Muller C, et al. Preliminary criteria for the very early diagnosis of systemic sclerosis: results of a Delphi consensus study from EULAR Scleroderma Trials and Research Group. Ann Rheum Dis. 2011;70:476-81.
Hachulla E, Launay D. Diagnosis and classification of systemic sclerosis. Clin Rev Allergy Immunol. 2011;40:78-83.
Roberts CG, Hummers LK, Ravich WJ, Wigley FM, Hutchins G. A case-controlled study of the pathology of oesophageal disease in systemic sclerosis (scleroderma). Gut. 2006;55:1697-703.
Bussone G, Bérezné A, Pestre V, Guillevin L, Mouthon L. The scleroderma kidney: progress is risk factors, therapy, and prevention. Curr Rheumatol Rep. 2011;13:37-43.
Chen AY, Zirwas MJ, Heffernan MP. Nephrogenic systemic fibrosis: a review. J Drugs Dermatol. 2010;9:829-34.
Castro SV, Jimenez SA. Biomarkers in systemic sclerosis. Biomarkers in medicine. 2010;4(1):133-47
Tashkin DP, Celli B, Senn S, Goldin J, Roth MD, Furst DE, Metersky M. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med. 2006;354:2655-66.
Hoyles RK, Ellis RW, Wellsbury J, Lees B, Newlands P, Goh NS, du Bois RM. A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum. 2006;54:3962-70.
Charles C, Clements P, Furst DE. Systemic sclerosis: hypothesis-driven treatment strategies. Lancet. 2006;367:1683-91.
Lee P, Langevitz P, Alderdice CA, Aubrey M, Baer PA, Baron M, Keystone EC. Mortality in systemic sclerosis (scleroderma). QJM. 1992;82:139-48.
Published
How to Cite
Issue
Section
License
Warning of rights of author
The authors that publish in this journal agree with the following terms:
The authors conserve the rights of author and concede to the journal the right of the first publication, fulfilling with the license Creative Commons Attribution License that allows to others share the work with recognition of the authorship of their articles, and the initial publication in this journal.
The authors can establish separately additional agreements for the no exclusive distribution of the version of the work published in the journal (for example, situate it in an institutional repository, in a personal blog or publish it partial or totally in a book), with a recognition of their initial publication in this journal.
To be able to send the manuscript or part of him passed three months of published, for his evaluation to other publishers, identifying it or not with the same title; whenever allusion is made to our journale and know it the new publisher.
The publishing committee of the Cuban Journal of Rheumatology authorizes to other publishers, to reproduce the articles published in our magazine, whenever it indicate the origin of the same.
The authors should send a document in Office Word application format through the electronic address of the magazine with a similar format to that we include next:
---------------------------------------------------------------------------------------------------------------------
Statement of authorship and cede of articles for the publication of the scientific work in the Cuban Journal of Rheumatology
Date:
Those who subscribe certify that are the authors of the work:
Of this form communicate the originality of our article clearing that the concepts and knowledges of other authors that have included in the text of the article, have been quoted properly in the bibliography.
We do proof besides that the article in question is original and has not been published, total neither partially, in another journal.
To be approved for his publication in the Cuban Journal of Rheumatology, do secession of the rights of publication to the same one through the method that realizes it usually.
In front of any catchword that exist by the article that send to evaluate, relieve of of the responsibility to the Cuban Journal of Rheumatology holding us responsible with all the difficulties that can berelated by any situation.
We include to continuation the name and the signature of all authors and collaborators of this article.
Name: Signature:
